UY26962A1 - Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento - Google Patents

Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento

Info

Publication number
UY26962A1
UY26962A1 UY26962A UY26962A UY26962A1 UY 26962 A1 UY26962 A1 UY 26962A1 UY 26962 A UY26962 A UY 26962A UY 26962 A UY26962 A UY 26962A UY 26962 A1 UY26962 A1 UY 26962A1
Authority
UY
Uruguay
Prior art keywords
preparation
crystalline
monohidrate
procedure
medicinal product
Prior art date
Application number
UY26962A
Other languages
English (en)
Inventor
Rolf Banholzer
Peter Sieger
Christian Kulinna
Michael Trunk
Manfred Ludwig August Graulich
Peter Specht
Helmut Meissner
Andreas Mathes
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7659568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY26962(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY26962A1 publication Critical patent/UY26962A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El invento se refiere a un monohidrato cristalino de bromuro de (1 alfa, 2 beta, 4 beta, 5 alfa, 7 beta) - 7 - ( hidroxi - di - 2 - tienil - acetil) oxil) - 9, 9 - dimetil - 3 - oxa -9- azonia - triciclo (3.3.1.0. 2,4) nonano, a un procedimiento para su preparación, así como a su utilización para la preparación de un medicamento, particularmente para la preparación de un medicamento con efecto anticolinérgico.
UY26962A 2000-10-12 2001-10-10 Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento UY26962A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10050621 2000-10-12

Publications (1)

Publication Number Publication Date
UY26962A1 true UY26962A1 (es) 2002-06-20

Family

ID=7659568

Family Applications (2)

Application Number Title Priority Date Filing Date
UY26962A UY26962A1 (es) 2000-10-12 2001-10-10 Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY34901A UY34901A (es) 2000-10-12 2013-07-11 ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY34901A UY34901A (es) 2000-10-12 2013-07-11 ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.

Country Status (47)

Country Link
EP (2) EP1326862B1 (es)
JP (1) JP3764422B2 (es)
KR (1) KR100823860B1 (es)
CN (2) CN100519558C (es)
AP (1) AP1572A (es)
AR (2) AR034389A1 (es)
AT (1) ATE276253T1 (es)
AU (2) AU1499602A (es)
BG (1) BG66161B1 (es)
BR (1) BR0114584A (es)
CA (1) CA2425539C (es)
CR (1) CR6938A (es)
CZ (1) CZ301841B6 (es)
DE (1) DE50103666D1 (es)
DK (1) DK1326862T3 (es)
DZ (1) DZ3478A1 (es)
EA (1) EA004381B1 (es)
EC (1) ECSP034540A (es)
EE (1) EE04567B1 (es)
EG (1) EG24142A (es)
ES (1) ES2228965T3 (es)
GE (1) GEP20063905B (es)
HK (2) HK1060567A1 (es)
HR (1) HRP20030276B1 (es)
HU (1) HU226830B1 (es)
IL (2) IL155335A0 (es)
IS (1) IS2339B (es)
MA (1) MA25842A1 (es)
ME (2) MEP40008A (es)
MX (1) MXPA03003221A (es)
MY (1) MY126931A (es)
NO (1) NO328465B1 (es)
NZ (1) NZ525733A (es)
OA (1) OA12403A (es)
PE (1) PE20020422A1 (es)
PL (1) PL207870B1 (es)
PT (1) PT1326862E (es)
RS (1) RS50218B (es)
SA (1) SA01220412B1 (es)
SI (1) SI1326862T1 (es)
SK (1) SK287009B6 (es)
TR (1) TR200402579T4 (es)
TW (1) TW589313B (es)
UA (1) UA74215C2 (es)
UY (2) UY26962A1 (es)
WO (1) WO2002030928A1 (es)
ZA (1) ZA200302500B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
RS50441B (sr) * 2001-06-22 2010-03-02 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Kristalni antiholinergik, postupak za njegovo pripremanje i njegova primena u proizvodnji leka
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
SG137859A1 (en) 2003-11-03 2007-12-28 Boehringer Ingelheim Int Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
ATE453641T1 (de) * 2003-11-03 2010-01-15 Boehringer Ingelheim Int Neues kristallines anhydrat mit anticholinerger wirksamkeit
SG149876A1 (en) * 2003-11-03 2009-02-27 Boehringer Ingelheim Int Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
DE102004016179A1 (de) * 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
KR101287460B1 (ko) 2004-04-22 2013-07-23 베링거 인겔하임 인터내셔날 게엠베하 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE602004020337D1 (de) 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
US20060079544A1 (en) * 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
BRPI0517282A (pt) * 2004-10-21 2008-10-07 Boehringer Ingelheim Int blister para inaladores
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
CA2605688A1 (en) 2005-04-28 2006-11-02 Boehringer Ingelheim International Gmbh Compounds for treating inflammatory diseases
CN101166738B (zh) 2005-05-02 2011-06-01 贝林格尔·英格海姆国际有限公司 噻托溴铵的新晶型
MX2007013691A (es) * 2005-05-02 2008-01-21 Boehringer Ingelheim Int Nuevas formas cristalinas de bromuro de tiotropio.
NZ583872A (en) * 2005-06-15 2011-10-28 Boehringer Ingelheim Int Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
DE102005030733A1 (de) 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
KR20080039974A (ko) * 2005-08-06 2008-05-07 베링거 인겔하임 인터내셔날 게엠베하 중증 지속성 천식의 치료에서 티오트로퓸 염의 용도
KR101360803B1 (ko) 2005-08-15 2014-02-11 베링거 인겔하임 인터내셔날 게엠베하 베타모방제의 제조방법
TWI396541B (zh) 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
US7423146B2 (en) 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
WO2007075838A2 (en) * 2005-12-19 2007-07-05 Sicor Inc. Pure and stable tiotropium bromide
ES2396978T5 (es) 2005-12-19 2015-12-04 Sicor, Inc. Forma cristalina novedosa de bromuro de tiotropio y procedimiento para la preparación de la misma
EA015353B1 (ru) * 2006-01-04 2011-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение солей тиотропия для лечения персистирующей астмы средней тяжести
NZ563488A (en) 2006-04-19 2010-04-30 Boehringer Ingelheim Int Dihydrothienopyrimidines for the treatment of inflammatory diseases
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US20080051582A1 (en) 2006-07-10 2008-02-28 Sicor Inc. Process for the preparation of tiotropium bromide
WO2008017637A1 (de) 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
UY30550A1 (es) 2006-08-22 2008-03-31 Boehringer Ingelheim Int Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos
EP1923393A1 (en) * 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2215092B1 (de) 2007-10-19 2012-01-25 Boehringer Ingelheim International GmbH Substituierte piperidino-dihydrothienopyrimidine
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
US20100272811A1 (en) * 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
KR101754698B1 (ko) 2008-12-19 2017-07-26 센트렉시온 테라퓨틱스 코포레이션 염증, 천식 및 ｃｏｐｄ 치료용 ｃｃｒ2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
EP2403851B1 (en) 2009-03-06 2015-06-17 Mahmut Bilgic New crystalline forms of tiotropium bromide
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
NZ624602A (en) 2009-08-07 2015-11-27 Generics Uk Ltd Anhydrate of tiotropium bromide
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
EA024397B1 (ru) 2009-12-17 2016-09-30 Сентрекшн Терапьютикс Корпорейшн Новые антагонисты рецептора ccr2 и их применение
NZ600857A (en) 2010-01-29 2014-06-27 Boehringer Ingelheim Int Substituted naphthyridines and their use as syk kinase inhibitors
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
EP2668177B1 (en) 2011-01-28 2014-10-22 Boehringer Ingelheim International GmbH Substituted pyridinyl-pyrimidines and their use as medicaments
TR201102068A2 (tr) * 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropyum bromür içeren kristal maddeler
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
MX336224B (es) 2011-07-26 2016-01-12 Boehringer Ingelheim Int Quinolinas sustituidas y su uso como medicamentos.
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
CZ304368B6 (cs) 2011-11-28 2014-04-02 Zentiva, K.S. Směsný solvát tiotropium bromidu a způsob jeho přípravy
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
UA115888C2 (uk) 2012-11-05 2018-01-10 Зентіва, К.С. Стабілізація сольватів тіотропію
EP2913332A1 (en) * 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
EP3119765B1 (en) 2014-03-19 2019-07-17 Boehringer Ingelheim International GmbH Heteroaryl syk inhibitors
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
RU2567539C1 (ru) * 2015-02-04 2015-11-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ (1α,2β,4β,5α,7β-7)-[(ГИДРОКСИДИ-2-ТИЕНИЛАЦЕТИЛ)ОКСИ]-9,9-ДИМЕТИЛ-3-ОКСА-9-АЗОНИАТРИЦИКЛО[3.3.1.02,4]НОНАН БРОМИДА МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3414243A1 (en) 2016-02-11 2018-12-19 Sima Patent Ve Lisanslama Hizmetleri Ltd. STI Crystalline form of tiotropium bromide anhydrate
EP3430011A4 (en) * 2016-11-04 2019-08-14 Sima Patent Ve Lisanslama Hizmetleri Ltd. STI NOVEL ACTIVE SUBSTANCE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SK280911B6 (sk) * 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostriedok
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
PT1102579E (pt) * 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais

Also Published As

Publication number Publication date
HUP0301022A2 (hu) 2003-10-28
CN1733761A (zh) 2006-02-15
CZ301841B6 (cs) 2010-07-07
AU1499602A (en) 2002-04-22
MY126931A (en) 2006-10-31
RS50218B (sr) 2009-07-15
IS6772A (is) 2003-04-09
MXPA03003221A (es) 2004-12-03
MA25842A1 (fr) 2003-07-01
EE04567B1 (et) 2005-12-15
ECSP034540A (es) 2003-07-25
MEP40008A (en) 2011-02-10
BG66161B1 (bg) 2011-09-30
AP1572A (en) 2006-02-13
TW589313B (en) 2004-06-01
ES2228965T3 (es) 2005-04-16
JP3764422B2 (ja) 2006-04-05
SK4362003A3 (en) 2003-08-05
EA004381B1 (ru) 2004-04-29
WO2002030928A1 (de) 2002-04-18
HUP0301022A3 (en) 2005-12-28
AU2002214996B2 (en) 2007-03-15
ZA200302500B (en) 2004-04-22
BR0114584A (pt) 2003-08-26
AP2003002775A0 (en) 2003-03-31
AR068527A2 (es) 2009-11-18
IL155335A0 (en) 2003-11-23
YU27303A (sh) 2006-05-25
PE20020422A1 (es) 2002-06-28
BG107687A (bg) 2003-09-30
CA2425539A1 (en) 2003-04-11
UA74215C2 (uk) 2005-11-15
NO20031694D0 (no) 2003-04-11
TR200402579T4 (tr) 2004-12-21
IL155335A (en) 2009-02-11
EP1468998A1 (de) 2004-10-20
CN1221549C (zh) 2005-10-05
EE200300171A (et) 2003-06-16
GEP20063905B (en) 2006-08-25
UY34901A (es) 2015-02-27
PT1326862E (pt) 2004-11-30
PL366041A1 (en) 2005-01-24
DK1326862T3 (da) 2004-11-22
KR100823860B1 (ko) 2008-04-21
EG24142A (en) 2008-08-06
SI1326862T1 (en) 2005-02-28
HRP20030276A2 (en) 2005-02-28
OA12403A (en) 2006-04-18
IS2339B (is) 2008-02-15
HK1060567A1 (en) 2004-08-13
CN100519558C (zh) 2009-07-29
CR6938A (es) 2004-10-28
PL207870B1 (pl) 2011-02-28
KR20030042008A (ko) 2003-05-27
NO20031694L (no) 2003-04-11
HRP20030276B1 (en) 2006-02-28
HK1086557A1 (en) 2006-09-22
CN1469877A (zh) 2004-01-21
SK287009B6 (sk) 2009-09-07
JP2004526668A (ja) 2004-09-02
EA200300457A1 (ru) 2003-10-30
DE50103666D1 (de) 2004-10-21
CA2425539C (en) 2007-04-03
DZ3478A1 (fr) 2002-04-18
AR034389A1 (es) 2004-02-25
NZ525733A (en) 2005-01-28
EP1326862B1 (de) 2004-09-15
SA01220412B1 (ar) 2006-11-05
HU226830B1 (en) 2009-11-30
NO328465B1 (no) 2010-02-22
ME00243B (me) 2011-05-10
ATE276253T1 (de) 2004-10-15
EP1326862A1 (de) 2003-07-16

Similar Documents

Publication Publication Date Title
UY26962A1 (es) Monohidrato cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
ECSP045310A (es) Material micronizado cristalino del bromuro de tiotropio
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
UY27388A1 (es) Nuevos compuestos
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
MX9205236A (es) Amino-propanos sustituidos, procedimientos para su preparacion y su utilizacion.
AR026451A1 (es) Compuestos heterociclicos sililados
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR036110A1 (es) Eurotinona y derivados de la misma, procedimiento para su preparacion, un microorganismo, composiciones farmaceuticas, procedimiento para su produccion, el uso de dichos derivados y composiciones para la preparacion de medicamentos, y uso de dicho microorganismo
CR7442A (es) Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas
ECSP024362A (es) Sustituido 1-aminoalquil-lactamas y su uso como antagonistas de receptores muscarinicos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20130729